Biological basis of differential susceptibility to hepatocarcinogenesis among mouse strains

Journal of Toxicologic Pathology

Volumn 22, Issue 1, 2009, Pages 11-33

  Maronpot, Robert R ^a  

^a Maronpot Consulting LLC   (United States)

Author keywords

Animal models; Cancer susceptibility; Genetics; Halogenated hydrocarbons; Non genotoxic carcinogens; Phenobarbital

Indexed keywords

HALOGENATED HYDROCARBON; PHENOBARBITAL;

APOPTOSIS; BIOASSAY; BODY WEIGHT; CANCER MODEL; CANCER SUSCEPTIBILITY; CASTRATION; CELL COMMUNICATION; CELL PROLIFERATION; CHEMICAL CARCINOGENESIS; DNA DAMAGE; DNA METHYLATION; ENZYME INDUCTION; GENETIC ENGINEERING; GENETIC SUSCEPTIBILITY; GENOME IMPRINTING; INBRED STRAIN; LIVER ADENOMA; LIVER CARCINOGENESIS; LIVER CARCINOMA; LIVER CELL CARCINOMA; LIVER TUMOR; NONHUMAN; ONCOGENE; ORCHIECTOMY; OVARIECTOMY; REVIEW; STRAIN DIFFERENCE; TUMOR SUPPRESSOR GENE; VIRUS INFECTION;

EID: 70349680623     PISSN: 09149198     EISSN: None     Source Type: Journal    
DOI: 10.1293/tox.22.11     Document Type: Review

References (247)

1. Butler WH and Newberne PM. Mouse Hepatic Neoplasia. Elsevier Scientific Publishing Company, New York. 1975.
2. Butterworth BE, Slaga TJ, Farland W, and McClain RM. Chemically Induced Cell Proliferation. Implications for Risk Assessment. Wiley-Liss, New York. 1991.
3. Chambers PL, Henschler D, and Oesch F. Mouse Liver Tumors. Proceedings of the European Society of Toxicology. Springer-Verlag, New York. 1987.
4. Ito N and Sugano H. Modification of Tumor Development in Rodents. KARGER, New York. 1991.
5. McClain RM, Slaga TJ, LeBoeuf R, and Pitot H. Growth Factors and Tumor Promotion. Implications for Risk Assessment. Wiley-Liss, New York. 1995.
6. Popp JA. Mouse Liver Neoplasia. Current Perspectives. Hemisphere Publishing Company, New York. 1984.
7. Stevenson DE, McClain RM, Popp JA, Slaga TJ, Ward JM, and Pitot HC. Mouse Liver Carcinogenesis. Mechanisms and Species Comparisons. Wiley-Liss, New York. 1990.
8. Vainio H, Magee P, McGregor D, and McMichael AJ. Mechanisms of Carcinogenesis in Risk Identification. IARC Scientific Publications, Lyon. 1992.
9. Alden CL, Smith PF, Piper CE, and Brej L. A critical appraisal of the value of the mouse cancer bioassay in safety assessment. Toxicol Pathol. 24: 722-725. 1996.
10. Frazer KA, Eskin E, Kang HM, Bogue MA, Hinds DA, Beilharz EJ, Gupta RV, Montgomery J, Morenzoni MM, Nilsen GB, Pethiyagoda CL, Stuve LL, Johnson FM, Daly MJ, Wade CM, and Cox DR. A sequence-based variation map of 8.27 million SNPs in inbred mouse strains. Nature. 448: 1050-1053. 2007.
11. Beck JA, Lloyd S, Hafezparast M, Lennon-Pierce M, Eppig JT, Festing MF, and Fisher EM. Genealogies of mouse inbred strains. Nat Genet. 24: 23-25. 2000.
12. Guénet JL and Bonhomme F. Origin of the Laboratory Mouse and Related Subspecies. In: The Laboratory Mouse, H Hedrich (ed). Elsevier, Amsterdam. 3-13. 2004.
13. Rao GN and Boorman GA. History of the B6C3F1 Mouse. In: Pathology of the Mouse, RR Maronpot (ed). Cache River Press, Vienna, IL. 1-6. 1999.
14. Russell E. Origins and history of mouse inbred strains: Contributions of clarence cook little. In: Origins of Inbred Mice, HI Morse (ed). AcademicPress, New York. 33-43. 1978.
15. Strong L. The origin of some inbred mice. Cancer Res. 2: 531-539. 1942.
16. Innes JR, Ulland BM, Valerio MG, Petrucelli L, Fishbein L, Hart ER, Pallotta AJ, Bates RR, Falk HL, Gart JJ, Klein M, Mitchell I, and Peters J. Bioassay of pesticides and industrial chemicals for tumorigenicity in mice: a preliminary note. J Natl Cancer Inst. 42: 1101-1114. 1969.
17. Maronpot RR, Haseman JK, Boorman GA, Eustis SE, Rao GN, and Huff JE. Liver lesions in B6C3F1 mice: the National Toxicology Program, experience and position. Arch Toxicol Suppl. 10: 10-26. 1987.
18. McClain RM, Keller D, Casciano D, Fu P, MacDonald J, Popp J, and Sagartz J. Neonatal mouse model: review of methods and results. Toxicol Pathol. 29 (Suppl): 128-137. 2001.
19. Vesselinovitch SD, Rao KV, Mihailovich N, Rice JM, and Lombard LS. Development of broad spectrum of tumors by ethylnitrosourea in mice and the modifying role of age, sex, and strain. Cancer Res. 34: 2530-2538. 1974.
20. Hanigan MH, Kemp CJ, Ginsler JJ, and Drinkwater NR. Rapid growth of preneoplastic lesions in hepatocarcinogen-sensitive C3H/HeJ male mice relative to C57BL/6J male mice. Carcinogenesis. 9: 885-890. 1988.
21. Moore MR, Drinkwater NR, Miller EC, Miller JA, and Pitot HC. Quantitative analysis of the time-dependent development of glucose-6-phosphatase-deficient foci in the livers of mice treated neonatally with diethylnitrosamine. Cancer Res. 41: 1585-1593. 1981.
22. Vesselinovitch SD and Mihailovich N. Kinetics of diethylnitrosamine hepatocarcinogenesis in the infant mouse. Cancer Res. 43: 4253-4259. 1983.
23. Lee GH, Nomura K, and Kitagawa T. Comparative study of diethylnitrosamine-initiated two-stage hepatocarcinogenesis in C3H, C57BL and BALB mice promoted by various hepatopromoters. Carcinogenesis. 10: 2227-2230. 1989.
24. Hanigan MH, Winkler ML, and Drinkwater NR. Partial hepatectomy is a promoter of hepatocarcinogenesis in C57BL/6J male mice but not in C3H/ HeJ male mice. Carcinogenesis. 11: 589-594. 1990.
25. Lee GH. Paradoxical effects of phenobarbital on mouse hepatocarcinogenesis. Toxicol Pathol. 28: 215-225. 2000.
26. Klaunig JE, Ruch RJ, and Pereira MA. Carcinogenicity of chlorinated methane and ethane compounds administered in drinking water to mice. Environ Health Perspect. 69: 89-95. 1986.
27. Sandgren EP, Luetteke NC, Qiu TH, Palmiter RD, Brinster RL, and Lee DC. Transforming growth factor alpha dramatically enhances oncogene-induced carcinogenesis in transgenic mouse pancreas and liver. Mol Cell Biol. 13: 320-330. 1993.
28. Sandgren EP and Merlino G. Hepatocarcinogenesis in transgenic mice. Prog Clin Biol Res. 391: 213-222. 1995.
29. Enomoto A, Sandgren EP, and Maronpot RR. Interactive effects of c-myc and transforming growth factor alpha transgenes on liver tumor development in simian virus 40 T antigen transgenic mice. Vet Pathol. 35: 283-291. 1998.
30. Sandgren EP, Quaife CJ, Pinkert CA, Palmiter RD, and Brinster RL. Oncogene-induced liver neoplasia in transgenic mice. Oncogene. 4: 715-724. 1989.
31. Cullen JM, Sandgren EP, Brinster RL, and Maronpot RR. Histologic characterization of hepatic carcinogenesis in transgenic mice expressing SV40 T-antigens. Vet Pathol. 30: 111-118. 1993.
32. Rogler CE, Yang D, Rossetti L, Donohoe J, Alt E, Chang CJ, Rosenfeld R, Neely K, and Hintz R. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J Biol Chem. 269: 13779-13784. 1994.
33. Enomoto A, Sandgren EP, and Maronpot RR. Altered differentiation of hepatocytes in a transgenic mouse model of hepatocarcinogenesis. Toxicol Pathol. 26: 570-578. 1998.
34. Lakhtakia R and Panda SK. Transgenic mouse models and hepatocellular carcinoma: future prospects. Trop Gastroenterol. 21: 91-94. 2000.
35. Singh M and Kumar V. Transgenic mouse models of hepatitis B virus-associated hepatocellular carcinoma. Rev Med Virol. 13: 243-253. 2003.
36. Chisari FV. Hepatitis B virus transgenic mice: insights into the virus and the disease. Hepatology. 22: 1316-1325. 1995.
37. Koike K. Hepatitis B virus HBx gene and hepatocarcinogenesis. Intervirology. 38: 134-142. 1995.
38. Koike K, Moriya K, Iino S, Yotsuyanagi H, Endo Y, Miyamura T, and Kurokawa K. High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice. Hepatology. 19: 810-819. 1994.
39. Yu DY, Moon HB, Son JK, Jeong S, Yu SL, Yoon H, Han YM, Lee CS, Park JS, Lee CH, Hyun BH, Murakami S, and Lee KK. Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein. J Hepatol. 31: 123-132. 1999.
40. Lakhtakia R, Kumar V, Reddi H, Mathur M, Dattagupta S, and Panda SK. Hepatocellular carcinoma in a hepatitis B 'x' transgenic mouse model: A sequential pathological evaluation. J Gastroenterol Hepatol. 18: 80-91. 2003.
41. Huang SN and Chisari FV. Strong, sustained hepatocellular proliferation precedes hepatocarcinogenesis in hepatitis B surface antigen transgenic mice. Hepatology. 21: 620-626. 1995.
42. Naas T, Ghorbani M, Alvarez-Maya I, Lapner M, Kothary R, De Repentigny Y, Gomes S, Babiuk L, Giulivi A, Soare C, Azizi A, and Diaz-Mitoma F. Characterization of liver histopathology in a transgenic mouse model expressing genotype 1a hepatitis C virus core and envelope proteins 1 and 2. J Gen Virol. 86: 2185-2196. 2005.
43. Kemp CJ and Drinkwater NR. Genetic variation in liver tumor susceptibility, plasma testosterone levels, and androgen receptor binding in six inbred strains of mice. Cancer Res. 49: 5044-5047. 1989.
44. Bachowski S, Xu Y, Baker TK, Stevenson DE, Walborg EF Jr, and Klaunig JE. The potential role of oxidative stress in nongenotoxic carcinogenesis in the mouse liver. Prog Clin Biol Res. 391: 385-396. 1995.
45. Floyd RA. The role of 8-hydroxyguanine in carcinogenesis. Carcinogenesis. 11: 1447-1450. 1990.
46. Hinrichsen LI, Floyd RA, and Sudilovsky O. Is 8-hydroxydeoxyguanosine a mediator of carcinogenesis by a choline-devoid diet in the rat liver? Carcinogenesis. 11: 1879-1881. 1990.
47. Bilger A, Bennett LM, Carabeo RA, Chiaverotti TA, Dvorak C, Liss KM, Schadewald SA, Pitot HC, and Drinkwater NR. A potent modifier of liver cancer risk on distal mouse chromosome 1: linkage analysis and characterization of congenic lines. Genetics. 167: 859-866. 2004.
48. Drinkwater NR and Ginsler JJ. Genetic control of hepatocarcinogenesis in C57BL/6J and C3H/HeJ inbred mice. Carcinogenesis. 7: 1701-1707. 1986.
49. Andervont HB. Induction of hepatomas in Strain C3H mice with 4-o-tolylazo-o-toluidine and carbon tetrachloride.J Natl Cancer Inst. 20: 431-438. 1938.
50. Andervont HB. The occurrence of spontaneous and induced pulmonary and liver tumors in strain C3H mice. Pub Health Rep. 54: 1158-1169. 1939.
51. Burns EL and Schenken JR. Spontaneous primary hepatomas in mice of strain C3H: A study of incidence, sex distribution, and morbid anatomy. Am J Cancer. 39: 380-392. 1940.
52. Andervont H. Spontaneous tumors in subline of strain C3H mice. J Natl Cancer Inst. 1: 737-744. 1941.
53. Heston W. High incidence of spontaneous hepatomas and the increase of this incidence with urethan in C3H, C3Hf and C3He male mice. J Natl Cancer Inst. 24: 425-435. 1960.
54. Strong LC and Smith GM. Benign hepatomas in mice of the CBA strain. Am J Cancer. 27: 279-284. 1936.
55. Andervont HB. Studies on the occurrence of spontaneous hepatomas in mice of strains C3H and CBA. J Natl Cancer Inst. 11: 581-592. 1950.
56. Silverstone H. The effect of rice diets on the formation of induced and spontaneous hepatomas in mice. Cancer Res. 8: 309-317. 1948.
57. Smith GS, Walford RL, and Mickey MR. Lifespan and incidence of cancer and other diseases in selected long-lived inbred mice and their F 1 hybrids. J Natl Cancer Inst. 50: 1195-1213. 1973.
58. Frith CH and Wiley L. Spontaneous hepatocellular neoplasms and hepatic hemangiosarcomas in several strains of mice. Lab Anim Sci. 32: 157-162. 1982.
59. Della-Porta G, Dragani TA, and Sozzi G. Carcinogenic effects of infantile and long-term 2,3,7,8-tetrachlorodibenzo-p-dioxin treatment in the mouse. Tumori. 73: 99-107. 1987.
60. Diwan BA, Rice JM, Ohshima M, and Ward JM. Interstrain differences in susceptibility to liver carcinogenesis initiated by N-nitrosodiethylamine and its promotion by phenobarbital in C57BL/6NCr, C3H/HeNCrMTV- and DBA/2NCr mice. Carcinogenesis. 7: 215-220. 1986.
61. Dragani T, Sozzi G, and DellaPorta G. Spontaneous and Urethan-induced tumor incidence in B6C3F1 versus B6CF1 mice. Tumori. 70: 485-490. 1984.
62. Dragani TA, Manenti G, and Della Porta G. Genetic susceptibility to murine hepatocarcinogenesis is associated with high growth rate of NDEA-initiated hepatocytes. J Cancer Res Clin Oncol. 113: 223-229. 1987.
63. Pugh TD and Goldfarb S. Growth kinetics of microscopic hepatocellular neoplasms in carcinogen-resistant and carcinogen-responsive strains of mice. Cancer Res. 52: 280-284. 1992.
64. Herren-Freund SL and Pereira MA. Carcinogenicity of by-products of disinfection in mouse and rat liver. Environ Health Perspect. 69: 59-65. 1986.
65. Vesselinovitch SD. The sex-dependent difference in the development of liver tumors in mice administered dimethylnitrosamine. Cancer Res. 29: 1024-1027. 1969.
66. Frith CH, Kodell RL, and Littlefield NA. Biologic and morphologic characteristics of hepatocellular lesions in BALB/c female mice fed 2-acetylaminofluorene. J Environ Pathol Toxicol. 3: 121-138. 1980.
67. Heston W, Vlahakis G, and Desmukes B. Effects of the antifertility drug enovid in five strains of mice, with particular regard to carcinogenesis. J Natl Cancer Inst. 51: 209-224. 1973.
68. Flaks A. The susceptibility of various strains of neonatal mice to the carcinogenic effects of 9,10-dimethyl-1,2-benzanthracene. Eur J Cancer. 4: 579-585. 1968.
69. Kyriazis AP and Vesselinovitch SD. Transplantability and biological behavior of mouse liver tumors induced by ethylnitrosourea. Cancer Res. 33: 332-338. 1973.
70. Vesselinovitch SD, Itze L, Mihailovich N, and Rao KVN. Modifying role of partial hepatectomy and gonadectomy in ethylnitrosourea-induced hepatocarcinogenesis. Cancer Res. 40: 1538-1542. 1980.
71. Vesselinovitch SD, Koka M, Rao KV, Mihailovich N, and Rice JM. Prenatal multicarcinogenesis by ethylnitrosourea in mice. Cancer Res. 37: 1822-1828. 1977.
72. Lee GH, Nomura K, Kanda H, Kusakabe M, Yoshiki A, Sakakura T, and Kitagawa T. Strain specific sensitivity to diethylnitrosamine-induced carcinogenesis is maintained in hepatocytes of C3H/HeN in equilibrium with C57BL/6N chimeric mice. Cancer Res. 51: 3257-3260. 1991.
73. Poole TM and Drinkwater NR. Hormonal and genetic interactions in murine hepatocarcinogenesis. Prog Clin Biol Res. 391: 187-194. 1995.
74. Andervont HB. Induction of hepatomas in strain C3H mice with 4-o-tolyazo-o-toluidin and carbon tetrachloride. J Natl Cancer Inst. 20: 431-438. 1958.
75. Chiaverotti TA and Drinkwater NR. C57BR/cdJ hepatocarcinogen susceptibility genes act cell-autonomously in C57BR/cdJ<->C57BL/6J chimeras. Cancer Res. 63: 4914-4919. 2003.
76. Drinkwater NR and Bennett LM. Genetic control of carcinogenesis in experimental animals. In: Modification of Tumor Development in Rodents, N Ito, and H Sugano (eds). Karger, Basel. 1-20. 1991.
77. Lee GH, Bennett LM, Carabeo RA, and Drinkwater NR. Identification of hepatocarcinogen-resistance genes in DBA/2 mice. Genetics. 139: 387-395. 1995.
78. National-Cancer-Institute. Report on carcinogenesis bioassay of chloroform. US Department of Health, Education and Welfare, National Institutes of Health, National Cancer Institute Bethesda, MD. 1976.
79. Bull RJ, Brown JM, Meierhenry EA, Jorgenson TA, Robinson M, and Stober JA. Enhancement of the hepatotoxicity of chloroform in B6C3F1 mice by corn oil: implications for chloroform carcinogenesis. Environ Health Perspect. 69: 49-58. 1986.
80. Jorgenson TA, Meierhenry EF, Rushbrook CJ, Bull RJ, and Robinson M. Carcinogenicity of chloroform in drinking water to male Osborne-Mendel rats and female B6C3F1 mice. Fundam Appl Toxicol. 5: 760-769. 1985.
81. Pereira MA. Route of administration determines whether chloroform enhances or inhibits cell proliferation in the liver of B6C3F1 mice. Fundam Appl Toxicol. 23: 87-92. 1994.
82. Coffin JC, Ge R, Yang S, Kramer PM, Tao L, and Pereira MA. Effect of trihalomethanes on cell proliferation and DNA methylation in female B6C3F1 mouse liver. Toxicol Sci. 58: 243-252. 2000.
83. Bull RJ. Mode of action of liver tumor induction by trichloroethylene and its metabolites, trichloroacetate and dichloroacetate. Environ Health Perspect. 108 (Suppl 2): 241-259. 2000.
84. Tao L, Ge R, Xie M, Kramer PM, and Pereira MA. Effect of trichloroethylene on DNA methylation and expression of early-intermediate protooncogenes in the liver of B6C3F1 mice. J Biochem Mol Toxicol. 13: 231-237. 1999.
85. Caldwell JC and Keshava N. Key issues in the modes of action and effects of trichloroethylene metabolites for liver and kidney tumorigenesis. Environ Health Perspect. 114: 1457-1463. 2006.
86. Pereira MA. Carcinogenic activity of dichloroacetic acid and trichloroacetic acid in the liver of female B6C3F1 mice. Fundam Appl Toxicol. 31: 192-199. 1996.
87. Boorman GA. Drinking water disinfection byproducts: review and approach to toxicity evaluation. Environ Health Perspect. 107 (Suppl 1): 207-217. 1999.
88. Bull RJ, Sanchez IM, Nelson MA, Larson JL, and Lansing AJ. Liver tumor induction in B6C3F1 mice by dichloroacetate and trichloroacetate. Toxicology. 63: 341-359. 1990.
89. DeAngelo AB, George MH, and House DE. Hepatocarcinogenicity in the male B6C3F1 mouse following a lifetime exposure to dichloroacetic acid in the drinking water: dose-response determination and modes of action. J Toxicol Environ Health A. 58: 485-507. 1999.
90. Ge R, Yang S, Kramer PM, Tao L, and Pereira MA. The effect of dichloroacetic acid and trichloroacetic acid on DNA methylation and cell proliferation in B6C3F1 mice. J Biochem Mol Toxicol. 15: 100-106. 2001.
91. Pereira MA, Wang W, Kramer PM, and Tao L. Prevention by methionine of dichloroacetic acid-induced liver cancer and DNA hypomethylation in mice. Toxicol Sci. 77: 243-248. 2004.
92. Tao L, Yang S, Xie M, Kramer PM, and Pereira MA. Hypomethylation and overexpression of c-jun and c-myc protooncogenes and increased DNA methyltransferase activity in dichloroacetic and trichloroacetic acid-promoted mouse liver tumors. Cancer Lett. 158: 185-193. 2000.
93. DeAngelo AB, Daniel FB, McMillan L, Wernsing P, and Savage RE Jr. Species and strain sensitivity to the induction of peroxisome proliferation by chloroacetic acids. Toxicol Appl Pharmacol. 101: 285-298. 1989.
94. Zhou YC and Waxman DJ. Activation of peroxisome proliferator-activated receptors by chlorinated hydrocarbons and endogenous steroids. Environ Health Perspect. 106 (Suppl 4): 983-988. 1998.
95. Tao L, Kramer PM, Ge R, and Pereira MA. Effect of dichloroacetic acid and trichloroacetic acid on DNA methylation in liver and tumors of female B6C3F1 mice. Toxicol Sci. 43: 139-144. 1998.
96. Tao L, Li K, Kramer PM, and Pereira MA. Loss of heterozygosity on chromosome 6 in dichloroacetic acid and trichloroacetic acid-induced liver tumors in female B6C3F1 mice. Cancer Lett. 108: 257-261. 1996.
97. Pereira MA, Wang W, Kramer PM, and Tao L. DNA hypomethylation induced by non-genotoxic carcinogens in mouse and rat colon. Cancer Lett. 212: 145-151. 2004.
98. Stevenson DE, Walborg EF Jr, North DW, Sielken RL Jr, Ross CE, Wright AS, Xu Y, Kamendulis LM, and Klaunig JE. Monograph: reassessment of human cancer risk of aldrin/dieldrin. Toxicol Lett. 109: 123-186. 1999.
99. Davis KJ and Fitzhugh OG. Tumorigenic potential of aldrin and dieldrin for mice. Toxicol Appl Pharmacol. 4: 187-189. 1962.
100. Thorpe E and Walker AI. The toxicology of dieldrin (HEOD). II. Comparative long-term oral toxicity studies in mice with dieldrin, DDT, phenobarbitone, -BHC and -BHC. Food Cosmet Toxicol. 11: 433-442. 1973.
101. Walker AI, Thorpe E, and Stevenson DE. The toxicology of dieldrin (HEOD). I. Long-term oral toxicity studies in mice. Food Cosmet Toxicol. 11: 415-432. 1973.
102. Maronpot RR, Anna CH, Devereux TR, Lucier GW, Butterworth BE, and Anderson MW. Considerations concerning the murine hepatocarcinogenicity of selected chlorinated hydrocarbons. Prog Clin Biol Res. 391: 305-323. 1995.
103. Carmichael NG, Enzmann H, Pate I, and Waechter F. The significance of mouse liver tumor formation for carcinogenic risk assessment: results and conclusions from a survey of ten years of testing by the agrochemical industry. Environ Health Perspect. 105: 1196-1203. 1997.
104. McClain RM. Mouse liver tumors and microsomal enzyme-inducing drugs: experimental and clinical perspectives with phenobarbital. Prog Clin Biol Res. 331: 345-365. 1990.
105. Weghorst CM, Pereira MA, and Klaunig JE. Strain differences in hepatic tumor promotion by phenobarbital in diethylnitrosamine- and dimethylnitrosamine-initiated infant male mice. Carcinogenesis. 10: 1409-1412. 1989.
106. Klaunig JE, Pereira MA, Ruch RJ, and Weghorst CM. Dose-response relationship of diethylnitrosamine-initiated tumors in neonatal balb/c mice: effect of phenobarbital promotion. Toxicol Pathol. 16: 381-385. 1988.
107. Diwan BA, Rice JM, and Ward JM. Strain-dependent effects of phenobarbital on liver tumor promotion in inbred mice. Prog Clin Biol Res. 331: 69-83. 1990.
108. Diwan BA, Rice JM, Ward JM, Ohshima M, and Lynch PH. Inhibition by phenobarbital and lack of effect of amobarbital on the development of liver tumors induced by N-nitrosodiethylamine in juvenile B6C3F1 mice. Cancer Lett. 23: 223-234. 1984.
109. Pereira MA, Klaunig JE, Herren-Freund SL, and Ruch RJ. Effect of phenobarbital on the development of liver tumors in juvenile and adult mice. J Natl Cancer Inst. 77: 449-452. 1986.
110. Klaunig JE, Weghorst CM, and Pereira MA. Effect of the age of B6C3F1 mice on phenobarbital promotion of diethylnitrosamine-initiated liver tumors. Toxicol Appl Pharmacol. 90: 79-85. 1987.
111. Kolaja KL, Stevenson DE, Johnson JT, Walborg EF Jr, and Klaunig JE. Subchronic effects of dieldrin and phenobarbital on hepatic DNA synthesis in mice and rats. Fundam Appl Toxicol. 29: 219-228. 1996.
112. Kolaja KL, Stevenson DE, Walborg EF Jr, and Klaunig JE. Dose dependence of phenobarbital promotion of preneoplastic hepatic lesions in F344 rats and B6C3F1 mice: effects on DNA synthesis and apoptosis. Carcinogenesis. 17: 947-954. 1996.
113. Pereira MA. Comparison in C3H and C3B6F1 mice of the sensitivity to diethylnitrosamine-initiation and phenobarbital-promotion to the extent of cell proliferation. Carcinogenesis. 14: 299-302. 1993.
114. Goldsworthy TL and Fransson-Steen R. Quantitation of the cancer process in C57BL/6J, B6C3F1 and C3H/HeJ mice. Toxicol Pathol. 30: 97-105. 2002.
115. Goodman JI and Watson RE. Altered DNA methylation: a secondary mechanism involved in carcinogenesis. Annu Rev Pharmacol Toxicol. 42: 501-525. 2002.
116. Counts JL, Sarmiento JI, Harbison ML, Downing JC, McClain RM, and Goodman JL. Cell proliferation and global methylation status changes in mouse liver after phenobarbital and/or choline-devoid, methionine-deficient diet administration. Carcinogenesis. 17: 1251-1257. 1996.
117. Watson RE and Goodman JI. Effects of phenobarbital on DNA methylation in GC-rich regions of hepatic DNA from mice that exhibit different levels of susceptibility to liver tumorigenesis. Toxicol Sci. 68: 51-58. 2002.
118. Counts JL, McClain RM, and Goodman JI. Comparison of effect of tumor promoter treatments on DNA methylation status and gene expression in B6C3F1 and C57BL/6 mouse liver and in B6C3F1 mouse liver tumors. Mol Carcinog. 18: 97-106. 1997.
119. Ray JS, Harbison ML, McClain RM, and Goodman JI. Alterations in the methylation status and expression of the raf oncogene in phenobarbital-induced and spontaneous B6C3F1 mouse live tumors. Mol Carcinog. 9: 155-166. 1994.
120. Vorce RL and Goodman JI. Hypomethylation of ras oncogenes in chemically induced and spontaneous B6C3F1 mouse liver tumors. Mol Toxicol. 2: 99-116. 1989.
121. Vorce RL and Goodman JI. Hypomethylation of ras oncogenes in chemically induced and spontaneous B6C3F1 mouse liver tumors. J Toxicol Environ Health. 34: 367-384. 1991.
122. Bauer-Hofmann R, Buchmann A, Mahr J, Kress S, and Schwarz M. The tumour promoters dieldrin and phenobarbital increase the frequency of c-Ha-ras wild-type, but not of c-Ha-ras mutated focal liver lesions in male C3H/ He mice. Carcinogenesis. 13: 477-481. 1992.
123. Bauer-Hofmann R, Buchmann A, Wright AS, and Schwarz M. Mutations in the Ha-ras proto-oncogene in spontaneous and chemically induced liver tumours of the CF1 mouse. Carcinogenesis. 11: 1875-1877. 1990.
124. Bauer-Hofmann R, Klimek F, Buchmann A, Muller O, Bannasch P, and Schwarz M. Role of mutations at codon 61 of the c-Ha-ras gene during diethylnitrosamine-induced hepatocarcinogenesis in C3H/He mice. Mol Carcinog. 6: 60-67. 1992.
125. Ueda M, Kiatyama E, Nakazawa M, Tamura H, Kajihara R, Uchimoto H, Ueda A, Ishibashi S, Oka T, Iwajura K, and Kura K. 26-Week carcinogenicity study of phenobarbital in CB6F1-Tg rasH2 mice and examination of hepatic carcinogenicity of phenobarbital in CB6F1-Tg rasH2 mice initiated with N-diethylnitrosamine. Toxicol Pathol. 29 (Suppl): 257-258. 2001.
126. Vynckier A, Van Deun K, De Hoog S, Monbaliu J, Ligtvoet T, Wilson JT, De With P, Van Gompel J, Verbeeck J, Vandenberghe J, and Coussement W. Results of 9-month carcinogenicity testing with phenobarbital in transgenic XPA-/- and XPA -/-. p53+/- mice and wild-type C57BL/6 mice. Toxicol Pathol. 29 (Suppl): 278-280. 2001.
127. Sanders S and Thorgeirsson SS. Promotion of hepatocarcinogenesis by phenobarbital in c-myc/TGF-alpha transgenic mice. Mol Carcinog. 28: 168-173. 2000.
128. Dragani TA, Manenti G, Gariboldi M, De Gregorio L, and Pierotti MA. Genetics of liver tumor susceptibility in mice. Toxicol Lett. 82-83: 613-619. 1995.
129. Gariboldi M, Manent, G, Canzian F, Falvella FS, Pierotti MA, Della-Porta G, Binelli G, and Dragani TA. Chromosome mapping of murine susceptibility loci to liver carcinogenesis. Cancer Res. 53: 209-211. 1993.
130. Manenti G, Binelli G, Gariboldi M, Canzian F, De Gregorio L, Falvella FS, Dragani TA, and Pierotti MA. Multiple loci affect genetic predisposition to hepatocarcinogenesis in mice. Genomics. 23: 118-124. 1994.
131. Poole TM, Winkler ML, Kaehler DA, and Drinkwater NR. Two loci account for the sensitivity of male C57BR/cdJ mice to hepatocarcinogenesis. Proc Amer Assoc Cancer Res. 35: 122. 1994 (Abst. 726).
132. Lee G-H, Nomura K, Kanda H, Kusakabe M, Yoshiki A, Sakakura T, and Kitagawa T. Strain specific sensitivity to diethylnitrosamine-induced carcinogenesis is maintained in hepatocytes of C3H/HeN<->C57BL/6N chimeric mice. Cancer Res. 15: 3257-3260. 1991.
133. Condamine H, Custer RP, and Mintz B. Pure-strain and genetically mosaic liver tumors histochemically identified with the -glucuronidase marker in allophenic mice. Proc Natl Acad Sci USA. 68: 2032-2036. 1971.
134. Dragani TA, Manenti G, and Della-Porta G. Quantitative analysis of genetic susceptibility to liver and lung carcinogenesis in mice. Cancer Res. 51: 6299-6303. 1991.
135. Tsukamoto T, Inada K, Fukami H, Yamamoto M, Tanaka H, Kusakabe M, Bishop CE, and Tatematsu M. Mouse strain susceptibility to diethylnitrosamine induced hepatocarcinogenesis is cell autonomous whereas sex-susceptibility Is due to the micro-environment: analysis with C3H<->BALB/c sexually chimeric mice. Jpn J Cancer Res. 91: 665-673. 2000.
136. Klaunig JE, Siglin JC, Schafer LD, Hartnett JA, Weghorst CM, Olson MJ, and Hampton JA. Correlation between species and tissue sensitivity to chemical carcinogenesis in rodents and the induction of DNA synthesis. Prog Clin Biol Res. 369: 185-194. 1991.
137. Popp JA and Marsman DS. Chemically induced cell proliferation in liver carcinogenesis. Prog Clin Biol Res. 369: 389-395. 1991.
138. Larson JL, Wolf DC, and Butterworth BE. Induced cytolethality and regenerative cell proliferation in the livers and kidneys of male B6C3F1 mice given chloroform by gavage. Fundam Appl Toxicol. 23: 537-543. 1994.
139. Dragani TA, Manenti G, and Porta GD. Enhancing effects of carbon tetrachloride in mouse hepatocarcinogenesis. Cancer Lett. 31: 171-179. 1986.
140. Fransson-Steen R, Goldsworthy TL, Kedderis GL, and Maronpot RR. Furan-induced liver cell proliferation and apoptosis in female B6C3F1 mice. Toxicology. 118: 195-204. 1997.
141. Parker CM, Van Gelder GA, Chai EY, Gellatly JB, Serota DG, Voelker RW, and Vesselinovitch SD. Oncogenic evaluation of tetrachlorvinphos in the B6C3F1 mouse. Fundam Appl Toxicol. 5: 840-854. 1985.
142. Goodman JI and Counts JL. Hypomethylation of DNA: a possible nongenotoxic mechanism underlying the role of cell proliferation in carcinogenesis. Environ Health Perspect. 5: 169-172. 1993.
143. Kolaja KL, Stevenson DE, Walborg EF Jr, and Klaunig JE. The effect of dieldrin and phenobarbital on preneoplastic hepatic lesion growth in male F344 rat and B6C3F1 mouse. Prog Clin Biol Res. 391: 409-423. 1995.
144. Roberts RA, Nebert DW, Hickman JA, Richburg JH, and Goldsworthy TL. Perturbation of the mitosis/apoptosis balance: a fundamental mechanism in toxicology. Fundam Appl Toxicol. 38: 107-115. 1997.
145. Bursch W, Grasl-Kraupp B, Wastl U, Hufnagl K, Chabicovsky M, Taper H, and Schulte-Hermann R. Role of apoptosis for mouse liver growth regulation and tumor promotion: comparative analysis of mice with high (C3H/He) and low (C57Bl/6J) cancer susceptibility. Toxicol Lett. 149: 25-35. 2004.
146. Melnick RL and Huff J. Liver carcinogenesis is not a predicted outcome of chemically induced hepatocyte proliferation. Toxicol Ind Health. 9: 415-438. 1993.
147. Snyder RD, Pullman J, Carter JH, Carter HW, and DeAngelo AB. In vivo administration of dichloroacetic acid suppresses spontaneous apoptosis in murine hepatocytes. Cancer Res. 55: 3702-3705. 1995.
148. Frey S, Buchmann A, Bursch W, Schulte-Hermann R, and Schwarz M. Suppression of apoptosis in C3H mouse liver tumors by activated Ha-ras oncogene. Carcinogenesis. 21: 161-166. 2000.
149. Kolaja KL, Stevenson DE, Walborg EF Jr, and Klaunig JE. Selective dieldrin promotion of hepatic focal lesions in mice. Carcinogenesis. 17: 1243-1250. 1996.
150. James NH and Roberts RA. Species differences in response to peroxisome proliferators correlate in vitro with induction of DNA synthesis rather than suppression of apoptosis. Carcinogenesis. 17: 1623-1632. 1996.
151. Kolaja KL, Stevenson DE, Walborg EF Jr, and Klaunig JE. Reversibility of promoter induced hepatic focal lesion growth in mice. Carcinogenesis. 17: 1403-1409. 1996.
152. Moser GJ, Wolf DC, Harden R, Standeven AM, Mills J, Jirtle RL, and Goldsworthy TL. Cell proliferation and regulation of negative growth factors in mouse liver foci. Carcinogenesis. 17: 1835-1840. 1996.
153. James SJ and Muskhelishvili L. Rates of apoptosis and proliferation vary with caloric intake and may influence incidence of spontaneous hepatoma in C57BL/6 × C3H F1 mice. Cancer Res. 54: 5508-5510. 1994.
154. Klaunig JE, Kamendulis LM, and Xu Y. Epigenetic mechanisms of chemical carcinogenesis. Hum Exp Toxicol. 19: 543-555. 2000.
155. Parke DV and Ioannides C. Role of cytochrome p-450 in mouse liver tumor production. Prog Clin Biol Res. 331: 215-230. 1990.
156. Perera MI, Betschart JM, Virji MA, Katyal SL, and Shinozuka H. Free radical injury and liver tumor promotion. Toxicol Pathol. 15: 51-59. 1987.
157. Bachowski S, Xu Y, Stevenson DE, Walborg EF Jr, and Klaunig JE. Role of oxidative stress in the selective toxicity of dieldrin in the mouse liver. Toxicol Appl Pharmacol. 150: 301-309. 1998.
158. Butler WH. A review of the hepatic tumors related to mixed-function oxidase induction in the mouse. Toxicol Pathol. 24: 484-492. 1996.
159. Counts JL and Goodman JI. Hypomethylation of DNA: a nongenotoxic mechanism involved in tumor promotion. Toxicol Lett. 82-83: 663-672. 1995.
160. Laird PW and Jaenisch R. The role of DNA methylation in cancer genetic and epigenetics. Annu Rev Genet. 30: 441-464. 1996.
161. Shivapurkar N, Wilson MJ, Hoover KL, Mikol YB, Creasia D, and Poirier LA. Hepatic DNA methylation and liver tumor formation in male C3H mice fed methionine- and choline-deficient diets. J Natl Cancer Inst. 77: 213-217. 1986.
162. Niculescu MD and Zeisel SH. Diet, methyl donors and DNA methylation: interactions between dietary folate, methionine and choline. J Nutr. 132: 2333S-2335S. 2002.
163. De Souza AT, Yamada T, Mills JJ, and Jirtle RL. Imprinted genes in liver carcinogenesis. FASEB J. 11: 60-67. 1997.
164. Goodman JE, Jensen LT, He P, and Yager JD. Characterization of human soluble high and low activity catechol-O-methyltransferase catalyzed catechol estrogen methylation. Pharmacogenetics. 12: 517-528. 2002.
165. Ooasa T, Karasaki H, Kanda H, Nomura K, Kitagawa T, and Ogawa K. Loss of imprinting of the insulin-like growth factor II gene in mouse hepatocellular carcinoma cell lines. Mol Carcinog. 23: 248-253. 1998.
166. Jirtle RL. Genomic imprinting and cancer. Exp Cell Res. 248: 18-24. 1999.
167. Li X, Adam G, Cui H, Sandstedt B, Ohlsson R, and Ekstrom TJ. Expression, promoter usage and parental imprinting status of insulin-like growth factor II (IGF2) in human hepatoblastoma: uncoupling of IGF2 and H19 imprinting. Oncogene. 11: 221-229. 1995.
168. Wong G, Kawajiri K, and Negishi M. Gene family of male-specific testosterone 16 alpha-hydroxylase (C-P-450(16) alpha) in mouse liver: cDNA sequences, neonatal imprinting, and reversible regulation by androgen. Biochemistry. 26: 8683-8690. 1987.
169. Wylie AA, Pulford DJ, McVie-Wylie AJ, Waterland RA, Evans HK, Chen YT, Nolan CM, Orton TC, and Jirtle RL. Tissue-specific inactivation of murine M6P/IGF2R. Am J Pathol. 162: 321-328. 2003.
170. Maronpot RR, Fox T, Malarkey DE, and Goldsworthy TL. Mutations in the ras proto-oncogene: clues to etiology and molecular pathogenesis of mouse liver tumors. Toxicology. 101: 125-156. 1995.
171. Buchmann A, Bauer-Hofmann R, Mahr J, Drinkwater NR, Luz A, and Schwarz M. Mutational activation of the c-Ha-ras gene in liver tumors of different rodent strains: correlation with susceptibility to hepatocarcinogenesis. Proc Natl Acad Sci USA. 88: 911-915. 1991.
172. Dragani TA, Manenti G, Colombo BM, Falvella FS, Gariboldi M, Pierotti MA, and Della Porta G. Incidence of mutations at codon 61 of the Ha-ras gene in liver tumors of mice genetically susceptible and resistant to hepatocarcinogenesis. Oncogene. 6: 333-338. 1991.
173. Buchmann A, Mahr J, Bauer Hofmann R, and Schwarz M. Mutations at codon 61 of the Ha-ras proto-oncogene in precancerous liver lesions of the B6C3F1 mouse. Mol Carcinog. 2: 121-125. 1989.
174. Hong HH, Devereux TR, Roycroft JH, Boorman GA, and Sills RC. Frequency of ras mutations in liver neoplasms from B6C3F1 mice exposed to tetrafluoroethylene for two years. Toxicol Pathol. 26: 646-650. 1998.
175. Hilberg F, Aguzzi A, Howells N, and Wagner EF. c-jun is essential for normal mouse development and hepatogenesis. Nature. 365: 179-181. 1993.
176. Nelson MA, Sanchez IM, Bull RJ, and Sylvester SR. Increased expression of c-myc and c-Ha-ras in dichloroacetate and trichloroacetate-induced liver tumors in B6C3F1 mice. Toxicology. 64: 47-57. 1990.
177. Grisham JW. Interspecies comparison of liver carcinogenesis: implications for cancer risk assessment. Carcinogenesis. 18: 59-81. 1996.
178. Kemp CJ. Comparative hepatocellular cancer genetics [comment]. Am J Pathol. 154: 975-977. 1999.
179. Jones PA and Laird PW. Cancer epigenetics comes of age. Nat Genet. 21: 163-167. 1999.
180. Anna CH, Iida M, Sills RC, and Devereux TR. Expression of potential beta-catenin targets, cyclin D1, c-Jun, c-Myc, E-cadherin, and EGFR in chemically induced hepatocellular neoplasms from B6C3F1 mice. Toxicol Appl Pharmacol. 190: 135-145. 2003.
181. Devereux TR, Anna CH, Foley JF, White CM, Sills RC, and Barrett JC. Mutation of beta-catenin is an early event in chemically induced mouse hepatocellular carcinogenesis. Oncogene. 18: 4726-4733. 1999.
182. Agnew LR and Gardner WU. The incidence of spontaneous hepatomas in C3H, C3H (low milk factor), and CBA mice and the effect of estrogen and androgen on the occurrence of these tumors in C3H mice. Cancer Res. 12: 757-761. 1952.
183. Toh YC. Effect of neonatal castration on liver tumor induction by N-2-fluorenylacetamide in suckling BALB/c mice. Carcinogenesis. 2: 1219-1221. 1981.
184. Bugni JM, Poole TM, and Drinkwater NR. The little mutation suppresses DEN-induced hepatocarcinogenesis in mice and abrogates genetic and hormonal modulation of susceptibility. Carcinogenesis. 22: 1853-1862. 2001.
185. Vesselinovitch S. Perinatal mouse liver carcinogenesis in a sensitive carcinogenesis model and the role of the sex hormonal environment in tumor development. In: Mouse Liver Carcinogenesis: Mechanisms and Species Comparisons, DE Stevenson, RM McClain, JA Popp, TJ Slaga, JM Ward, and HC Pitot (eds). Vol. 331. Wiley-Liss, New York. 53-69. 1990.
186. Yamamoto R, Iishi H, Tatsuta M, Tsuji M, and Terada N. Roles of ovaries and testes in hepatocellular tumorigenesis induced in mice by 3′-methyl-4-dimethylaminoazobenzene. Int J Cancer. 49: 83-88. 1991.
187. Vesselinovitch SD and Mihailovich N. The effect of gonadectomy on the development of hepatomas induced by urethan. Cancer Res. 27: 1788-1791. 1967.
188. Kemp CJ and Drinkwater NR. The androgen receptor and liver tumor development in mice. Prog Clin Biol Res. 331: 203-214. 1990.
189. Abdo KM and Kari FW. The sensitivity of the NTP bioassay for carcinogen hazard evaluation can be modulated by dietary restriction. Exp Toxicol Pathol. 48: 129-137, 1996.
190. Newberne PM and Sotnikov AV. Diet: The neglected variable in chemical safety evaluations. Toxicol Pathol. 24: 746-756. 1996.
191. Hancock RL and Dickie MM. Biochemical, pathological, and genetic aspects of a spontaneous mouse hepatoma. J Natl Cancer Inst. 43: 407-415. 1969.
192. Rao GN and Crockett PW. Effect of diet and housing on growth, body weight, survival and tumor incidences of B6C3F1 mice in chronic studies. Toxicol Pathol. 31: 243-250. 2003.
193. Hart RW and Turturro A. Dietary restrictions and cancer. Environ Health Perspect. 105 (Suppl 4): 989-992. 1997.
194. Leakey JE, Seng JE, and Allaben WT. Body weight considerations in the B6C3F1 mouse and the use of dietary control to standardize background tumor incidence in chronic bioassays. Toxicol Appl Pharmacol. 193: 237-265. 2003.
195. Turturro A, Duffy P, Hart RW, and Allaben WT. Rationale for the use of dietary control in toxicity studies - B6C3F1 mouse. Toxicol Pathol. 24: 769-775. 1996.
196. Sheldon WG, Bucci TJ, Hart RW, and Turturro A. Age-related neoplasia in a lifetime study of ad libitum-fed and food-restricted B6C3F1 mice. Toxicol Pathol. 23: 458-476. 1995.
197. Fu PP, Dooley KL, Von Tungeln LS, Bucci T, Hart RW, and Kadlubar FF. Caloric restriction profoundly inhibits liver tumor formation after initiation by 6-nitrochrysene in male mice. Carcinogenesis. 15: 159-161. 1994.
198. Haseman JK, Boorman GA, and Huff J. Value of historical control data and other issues related to the evaluation of long-term rodent carcinogenicity studies. Toxicol Pathol. 25: 524-527. 1997.
199. Haseman JK, Bourbina J, and Eustis SL. Effect of individual housing and other experimental design factors on tumor incidence in B6C3F1 mice. Fundam Appl Toxicol. 23: 44-52. 1994.
200. Leakey JE, Seng JE, Latendresse JR, Hussain N, Allen LJ, and Allaben WT. Dietary controlled carcinogenicity study of chloral hydrate in male B6C3F1 mice. Toxicol Appl Pharmacol. 193: 266-280. 2003.
201. Waterland RA and Jirtle RL. Transposable elements: targets for early nutritional effects on epigenetic gene regulation. Mol Cell Biol. 23: 5293-5300. 2003.
202. Temme A, Buchmann A, Gabriel HD, Nelles E, Schwarz M, and Willecke K. High incidence of spontaneous and chemically induced liver tumors in mice deficient for connexin32. Curr Biol. 7: 713-716. 1997.
203. Yamasaki H, Krutovskikh V, Mesnil M, and Omori Y. Connexin genes and cell growth control. Arch Toxicol Suppl. 18: 105-114. 1996.
204. Yamasaki H, Krutovskikh V, Mesnil M, Tanaka T, Zaidan-Dagli ML, and Omori Y. Role of connexin (gap junction) genes in cell growth control and carcinogenesis. C R Acad Sci III. 322: 151-159. 1999.
205. Yamasaki H, Mesnil M, Omori Y, Mironov N, and Krutovskikh V. Intercellular communication and carcinogenesis. Mutat Res. 333: 181-188. 1995.
206. Ruch RJ, Fransson R, Flodstrom S, Warngard L, and Klaunig JE. Inhibition of hepatocyte gap junctional intercellular communication by endosulfan, chlordane and heptachlor. Carcinogenesis. 11: 1097-1101. 1990.
207. Klaunig JE, Ruch RJ, Hampton JA, Weghorst CM, and Hartnett JA. Gap-junctional intercellular communication and murine hepatic carcinogenesis. Prog Clin Biol Res. 331: 277-291. 1990.
208. Klaunig JE, Ruch RJ, and Weghorst CM. Comparative effects of phenobarbital, DDT, and lindane on mouse hepatocyte gap junctional intercellular communication. Toxicol Appl Pharmacol. 102: 553-563. 1990.
209. Yamasaki H, Krutovskikh V, Mesnil M, Columbano A, Tsuda H, and Ito N. Gap junctional intercellular communication and cell proliferation during rat liver carcinogenesis. Environ Health Perspect. 101 (Suppl 5): 191-197. 1993.
210. Yamasaki H, Omori Y, Zaidan-Dagli ML, Mironov N, Mesnil M, and Krutovskikh V. Genetic and epigenetic changes of intercellular communication genes during multistage carcinogenesis. Cancer Detect Prev. 23: 273-279. 1999.
211. Rao GN, Piegorsch WW, Crawford DD, Edmondson J, and Haseman JK. Influence of viral infections on body weight, survival, and tumor prevalence of B6C3F1 (C57BL/6N × C3H/HeN) mice in carcinogenicity studies. Fundam Appl Toxicol. 13: 156-164. 1989.
212. Grasl-Kraupp B, Ruttkay-Nedecky B, Mullauer L, Taper H, Huber W, Bursch W, and Schulte-Hermann R. Inherent increase of apoptosis in liver tumors: implications for carcinogenesis and tumor regression. Hepatology. 25: 906-912. 1997.
213. Hendrich S, Glauert HP, and Pitot HC. The phenotypic stability of altered hepatic foci: effects of withdrawal and subsequent readministration of phenobarbital. Carcinogenesis. 7: 2041-2045. 1986.
214. Malarkey DE, Devereux TR, Dinse GE, Mann PC, and Maronpot RR. Hepatocarcinogenicity of chlordane in B6C3F1 and B6D2F1 male mice: evidence for regression in B6C3F1 mice and carcinogenesis independent of ras proto-oncogene activation. Carcinogenesis. 16: 2617-2625. 1995.
215. Fremond B, Jouan H, Sameh AH, Le Gall E, Bergeron C, Manac'h A, Gruel Y, and Babut JM. [Tumors of the liver secondary to androgen therapy. Apropos of 2 cases in children]. Chir Pediatr. 28: 97-101. 1987.
216. McCaughan GW, Bilous MJ, and Gallagher ND. Long-term survival with tumor regression in androgen-induced liver tumors. Cancer. 56: 2622-2626. 1985.
217. Emerson QB, Nachtnebel KL, Penkava RR, and Rothenberg J. Oral-contraceptive-associated liver tumours. Lancet. 1: 1251. 1980.
218. Steinbrecher UP, Lisbona R, Huang SN, and Mishkin S. Complete regression of hepatocellular adenoma after withdrawal of oral contraceptives. Dig Dis Sci. 26: 1045-1050. 1981.
219. Greaves P, Irisarri E, and Monro AM. Hepatic foci of cellular and enzymatic alteration and nodules in rats treated with clofibrate or diethylnitrosamine followed by phenobarbital: their rate of onset and their reversibility. J Natl Cancer Inst. 76: 475-484. 1986.
220. Marsman DS and Popp JA. Biological potential of basophilic hepatocellular foci and hepatic adenoma induced by the peroxisome proliferator, Wy-14,643. Carcinogenesis. 15: 111-117. 1994.
221. Haseman JK, Huff J, and Boorman GA. Use of historical control data in carcinogenicity studies in rodents. Toxicol Pathol. 12: 126-135. 1984.
222. Haseman JK, Huff JE, Rao GN, Arnold JE, Boorman GA, and McConnell EE. Neoplasms observed in untreated and corn oil gavage control groups of F344/N rats and (C57BL/6N × C3H/HeN)F1 (B6C3F1) mice. J Natl Cancer Inst. 75: 975-984. 1985.
223. King-Herbert A and Thayer K. NTP workshop: animal models for the NTP rodent cancer bioassay: stocks and strains-should we switch? Toxicol Pathol. 34: 802-805. 2006.
224. Goodman D, Boorman G, and Strandberg J. Selection and use of the B6C3F1 mouse and F344 rat in long-term bioassays for carcinogenicity. In: Handbook of Carcinogen Testing, H Milman and EK Weisburger (eds). Noyes Publications, Park Ridge, NJ. 282-325. 1985.
225. Weisburger EK. History of the bioassay program of the National Cancer Institute. Prog Exp Tumor Res. 26: 187-201. 1983.
226. Maronpot RR. Considerations in the evaluation and interpretation of long-term animal bioassays for carcinogenicity. In: Handbook of Carcinogen Testing, H Milman and EK Weisburger (eds). Noyes Publication, Park Ridge, NJ. 372-382. 1985.
227. Allen DG, Pearse G, Haseman JK, and Maronpot RR. Prediction of rodent carcinogenesis: an evaluation of prechronic liver lesions as forecasters of liver tumors in NTP carcinogenicity studies. Toxicol Pathol. 32: 393-401. 2004.
228. Cohen SM. Human carcinogenic risk evaluation: an alternative approach to the two-year rodent bioassay. Toxicol Sci. 80: 225-229. 2004.
229. Goodman J, Ward J, Popp J, Klaunig J, and Fox T. Mouse liver carcinogenesis: mechanisms and relevance. Fundam Appl Toxicol. 17: 651-665. 1991.
230. Hardisty J. Value of the mouse carcinogenicity bioassay. Toxicol Pathol. 24: 720-721. 1996.
231. Mann P. The great mouse debate: should the mouse continue to be used for carcinogenicity studies? Toxicol Pathol. 24: 720. 1996.
232. Maronpot RR and Boorman GA. The contribution of the mouse in hazard identification studies. Toxicol Pathol. 24: 726-731. 1996.
233. Newberne P. How relevant are mice hepatomas to human risk? Toxicol Pathol. 11: 113-114. 1983.
234. Ward JM, Griesemer RA, and Weisburger EK. The mouse liver tumor as an endpoint in carcinogenesis tests. Toxicol Appl Pharmacol. 51: 389-397. 1979.
235. von Wittenau M and Estes P. The redundancy of mouse carcinogenicity bioassays. Fundam Appl Toxicol. 3: 631-639. 1983.
236. Melnick RL, Sills RC, Portier CJ, Roycroft JH, Chou BJ, Grumbein SL, and Miller RA. Multiple organ carcinogenicity of inhaled chloroprene (2-chloro-1,3-butadiene) in F344/N rats and B6C3F1 mice and comparison of dose-response with 1,3-butadiene in mice. Carcinogenesis. 20: 867-878. 1999.
237. Spalding JW, French JE, Stasiewicz S, Furedi-Machacek M, Conner F, Tice RR, and Tennant RW. Responses of transgenic mouse lines p53(+/-) and Tg.AC to agents tested in conventional carcinogenicity bioassays. Toxicol Sci. 53: 213-223. 2000.
238. Tennant RW and Zeiger E. Genetic toxicology: current status of methods of carcinogen identification. Environ Health Perspect. 100: 307-315. 1993.
239. Cohen SM. Human relevance of animal carcinogenicity studies. Regul Toxicol Pharmacol. 21: 75-80. 1995.
240. Grasso P, Sharratt M, and Cohen AJ. Role of persistent, non-genotoxic tissue damage in rodent cancer and relevance to humans. Annu Rev Pharmacol Toxicol. 31: 253-287. 1991.
241. Huff J. Value, validity, and historical development of carcinogenesis studies for predicting and confirming carcinogenic risk to humans. In: Carcinogenicity. Testing, Predicting, and Interpreting Chemical Effects, K Kitchin (eds). Marcel Dekker, New York. 21-123. 1999.
242. Huff J and Rall D. Relevance to humans of carcinogenicity results from laboratory animal toxicology studies. In: Public Health and Preventive Medicine, J Last and R Wallace (eds). Appleton & Lange, Norwalk, Connecticut. 433-440. 1992.
243. Maronpot RR, Flake G, and Huff J. Relevance of animal carcinogenesis findings to human cancer predictions and prevention. Toxicol Pathol. 32 (Suppl 1): 40-48. 2004.
244. Meek ME, Bucher JR, Cohen SM, Dellarco V, Hill RN, Lehman-McKeeman LD, Longfellow DG, Pastoor T, Seed J, and Patton DE. A framework for human relevance analysis of information on carcinogenic modes of action. Crit Rev Toxicol. 33: 591-653. 2003.
245. Monro A. How useful are chronic (life-span) toxicology studies in rodents in identifying pharmaceuticals that pose a carcinogenic risk to humans? Adverse Drug React Toxicol Rev. 12: 5-34. 1993.
246. Dellarco VL and Baetcke K. A risk assessment perspective: application of mode of action and human relevance frameworks to the analysis of rodent tumor data. Toxicol Sci. 86: 1-3. 2005.
247. Holsapple MP, Pitot HC, Cohen SM, Boobis AR, Klaunig JE, Pastoor T, Dellarco VL, and Dragan YP. Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol Sci. 89: 51-56. 2006.